Roche And Kosan To Initiate Phase 2 Cancer Development Program With Epothilone R1645 (KOS-1584)

Wed, 28 Feb 2007 02:00 PM EST

... Roche and Kosan Biosciences Incorporated (Nasdaq: KOSN) announced today that the companies have selected their second-generation epothilone R1645 (KOS- 1584) to advance into a Phase 2 clinical development program exploring clinical activity and safety in multiple solid tumor types. [click link for full article] ...